Targeting human melanoma neoantigens by T cell receptor gene therapy

Journal of Clinical Investigation

Volumn 126, Issue 3, 2016, Pages 854-858

  Leisegang, Matthias ^a   Kammertoens, Thomas ^a   Uckert, Wolfgang ^a,b   Blankenstein, Thomas ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; MELAN A; T LYMPHOCYTE RECEPTOR; CDK4 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; MUTATIONAL LOAD; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; T LYMPHOCYTE RECEPTOR GENE; TRANSGENIC MOUSE; TUMOR REGRESSION; AMINO ACID SEQUENCE; ANIMAL; DNA MUTATIONAL ANALYSIS; GENE THERAPY; GENETICS; IMMUNOLOGY; METABOLISM; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 4; DNA MUTATIONAL ANALYSIS; GENETIC THERAPY; HLA-A2 ANTIGEN; HUMANS; MART-1 ANTIGEN; MELANOMA; MICE, TRANSGENIC; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL;

EID: 84959898639     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI83465     Document Type: Article

References (27)

1. Robbins PF, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747-752.
2. van Rooij N, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013;31(32):e439-e442.
3. Rizvi NA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-128.
4. Blankenstein T, Leisegang M, Uckert W, Schreiber H. Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol. 2015;33:112-119.
5. Fritsch EF, Rajasagi M, Ott PA, Brusic V, Hacohen N, Wu CJ. HLA-binDing properties of tumor neoepitopes in humans. Cancer Immunol Res. 2014;2(6):522-529.
6. Engels B, et al. Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell. 2013;23(4):516-526.
7. Wölfel T, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995;269(5228):1281-1284.
8. Soufir N, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet. 1998;7(2):209-216.
9. Smalley KS, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther. 2008;7(9):2876-2883.
10. Kvistborg P, et al. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology. 2012;1(4):409-418.
11. Wilde S, et al. Dendritic cells pulsed with RNA encoDing allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood. 2009;114(10):2131-2139.
12. van Buuren MM, Calis JJ, Schumacher TN. High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. Oncoimmunology. 2014;3:e28836.
13. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Pérarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from 2 microglobulin (2m) HLA-A2.1 monochain transgenic H-2Db 2m double knockout mice. J Exp Med. 1997;185(12):2043-2051.
14. Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med. 2004;10(3):294-298.
15. Blankenstein T. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol. 2005;17(2):180-186.
16. Kawakami Y, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994;180(1):347-352.
17. Skipper JC, et al. Mass-spectrometric evaluation of HLA-A0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int J Cancer. 1999;82(5):669-677.
18. Valmori D, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol. 1998;160(4):1750-1758.
19. Borbulevych OY, Santhanagopolan SM, Hossain M, Baker BM. TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms. J Immunol. 2011;187(5):2453-2463.
20. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957;18(6):769-778.
21. Monach PA, Meredith SC, Siegel CT, Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity. 1995;2(1):45-59.
22. Yadav M, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515(7528):572-576.
23. Gubin MM, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577-581.
24. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature. 2005;437(7055):141-146.
25. Van Waes C, Monach PA, Urban JL, Wortzel RD, Schreiber H. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro. Tissue Antigens. 1996;47(5):399-407.
26. Johnson LA, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535-546.
27. Atkins MB, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-2116.